OncoGynecology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Search results for "Palbociclib"

Pfizer has announced that the randomized Phase 2 trial, PALOMA-1, of Palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pro ...

The CDK4/6 inhibitor Palbociclib ( Ibrance ) in combination with Letrozole ( Femara ) has become a standard first-line treatment for patients with luminal metastatic breast cancer ( MBC ) ( PALOMA-1 & ...

Genome-wide transcriptional analysis has identified a unique subset of androgen receptor (AR)+, estrogen receptor ( ER ) / progesterone receptor (PR)- breast cancer. The functional role of androgen ...